Aclaris Therapeutics, Inc.
ACRS- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001557746
No open-market purchases or sales by Aclaris Therapeutics, Inc. insiders were filed in the last 90 days; 148 institutions reported holding it in 13F filings for Q2 2026, worth $630.0M in total; no superinvestor holds it.
Q2 2023 vs. Q1 2023
How the institutions holding Aclaris Therapeutics, Inc. changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 149 | 133 | −16 |
| Shares | 71.6M | 71.1M | −465.6K (−0.7%) |
| Value | $579.3M | $737.2M | +$157.9M (+27.2%) |
New holders (11)
Institutions that held Aclaris Therapeutics, Inc. at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Logos Global Management LP | 525,000 | $5.44M | 0.75% |
| Lord, Abbett & Co. LLC | 398,352 | $4.13M | 0.01% |
| HSBC Holdings PLC | 249,842 | $2.61M | 0.00% |
| Polar Asset Management Partners Inc. | 125,600 | $1.30M | 0.03% |
| J. Goldman & Co LP | 90,939 | $943.0K | 0.05% |
| Los Angeles Capital Management LLC | 75,006 | $777.8K | 0.00% |
| Westwood Holdings Group Inc. | 51,023 | $529.0K | 0.00% |
| Walleye Trading LLC | 46,327 | $480.4K | 0.03% |
| Marshall Wace, LLP | 30,423 | $315.5K | 0.00% |
| D. E. Shaw & Co., Inc. | 28,923 | $299.9K | 0.00% |
| Lindbrook Capital, LLC | 34 | $353 | 0.00% |
Sold out (27)
Institutions that held Aclaris Therapeutics, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.